EUCTR2007-000558-30-GB进行中（未招募）不适用
A Multicentre, Randomised, Double-Blind, Double-Dummy, Crossover Study to Evaluate the Safety and Efficacy of AD 923 (Fentanyl Sublingual) in Comparison to Morphine Sulphate Immediate Release (MSIR) for the Treatment of Breakthrough Pain in Subjects with Malignancies
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •The subject is a male or female, at least 18 years of age.
- •Subjects with a malignancy who are receiving, and are tolerant to, opioid therapy for his or her underlying persistent cancer pain. The dose of background opioid therapy must be stable for at least 7 days prior to the screening visit and should not be changed during the study. The minimum dose of background opioid therapy should be 60 mg of morphine or morphine equivalent or 25 µg/hour transdermal fentanyl.
- •The subject must typically be experiencing 2 to 6 episodes of target breakthrough pain per day that require treatment and be willing and able to use opioid therapy as treatment.
- •If female, the subject has a negative urine pregnancy test and is not lactating, or has not been of childbearing potential for at least 3 months prior to study drug administration.
- •The subject is able and willing to understand the study and cooperate with all study instructions.
- •The subject is able and willing to provide written informed consent.
- •The subject has a life expectancy of =3 months.
- •The subject or his or her caregiver has easy, reliable access to a telephone.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •The subject is a female who is pregnant or lactating.
- •The subject has any respiratory or cardiac condition that, in the opinion of the investigator, may be clinically worsened by opioids.
- •The subject has any allergy to the AD 923 product or excipients, namely: fentanyl, dehydrated alcohol, menthol, saccharin, and citrate buffer; or to the MSIR product excipients, namely: morphine sulphate, lactose (anhydrous), pregelatinized maize starch, povidone, purified water, magnesium stearate, talc, and tablet coatings.
- •The subject has any neurological or psychiatric disease that, in the opinion of the investigator, would compromise data collection.
- •The subject has uncontrolled or rapidly escalating pain.
- •The subject has a history of alcohol or substance abuse within the last 2 years.
- •The subject has hepatic dysfunction as shown by alanine aminotransferase [ALT] and /or aspartate aminotransferase [AST] levels elevated more than 5 times the upper limit of normal.
- •The subject has renal dysfunction as shown by creatinine elevated more than 1.5 times the upper limit of normal.
- •The subject has any significant laboratory test results that, in the opinion of the investigator, will compromise subject safety or the conduct of the study.
- •The subject has uncontrolled infection.
- •The subject has received treatment with an investigational drug or has participated in a clinical study within 4 weeks of the screening visit.
- •The subject has had treatment with radiotherapy to a painful site within 14 days prior to study entry or has had any therapy that could alter pain or response to pain medication.
- •The subject is taking intrathecal or epidural forms of opioids.
- •The subject is taking any prohibited medications as described in the concomitant medications section (Section 6.3).
- •The subject has plans to undergo chemotherapy, radiotherapy, or surgery during the treatment period. The exception is that subjects may continue chemotherapy over the study period, provided it is not expected to alter the pain state or response to pain medication.
研究者
相似试验
进行中（未招募）
不适用
A Multicentre, Randomised, Double-Blind, Double-Dummy, Crossover Study to Evaluate the Safety and Efficacy of AD 923 (Fentanyl Sublingual) in Comparison to Morphine Sulphate Immediate Release (MSIR) for the Treatment of Breakthrough Pain in Subjects with MalignanciesEUCTR2007-000558-30-BESosei R&D Ltd150
进行中（未招募）
不适用
A Multicentre, Randomised, Double-Blind, Double-Dummy, Active Comparator Controlled, Parallel Group Study of COLAL PRED® in the Treatment of Moderate Acute Ulcerative Colitis.EUCTR2004-005032-35-HUAlizyme Therapeutics Limited890
进行中（未招募）
不适用
A Multicentre, Randomised, Double-Blind, Double-Dummy, Crossover Study to Evaluate the Safety and Efficacy of AD 923 (Fentanyl Sublingual) in Comparison to Morphine Sulphate Immediate Release (MSIR) for the Treatment of Breakthrough Pain in Subjects with MalignanciesEUCTR2005-002552-17-HUSosei R&D Ltd150
进行中（未招募）
不适用
A Multicentre, Randomised, Double-Blind, Double-Dummy, Active Comparator Controlled, Parallel Group Study of COLAL PRED® in the Treatment of Moderate Acute Ulcerative Colitis.EUCTR2004-005032-35-DKAlizyme Therapeutics Limited890
招募中
3 期
A study to check effectiveness of Dimethyl Fumarate Gastro-Resistant Hard Capsule in patients with Moderate to Severe Chronic Plaque Psoriasis.CTRI/2020/12/029611Alvogen Malta OutLicensing Ltd